YPrime Awarded Global Phase II Oncology Clinical Trial Which Will Utilize Proprietary eClinical Supply Forecasting Tool Combined With IRT
BOSTON and MALVERN, Pa., April 7, 2015 /PRNewswire/ -- Y-Prime, Inc., announced today that it has been awarded an international Phase II clinical trial to assess a new treatment for patients with Non-Small Cell Lung Carcinoma (NSCLC). This study will be conducted utilizing their proprietary eClinical Supply Forecasting tool (eCSF), along with their state-of-the-art Interactive Response Technology (IRT).
Throughout this trial, YPrime will be supporting world class selected sites to conduct the study with data driven metrics pulled from these tools. YPrime is dedicated to applying its leading edge eClinical technology to help forward unmet medical needs in the Biotech and Pharmaceutical industry.
"Our team is very pleased to continue helping Biotech and Pharmaceutical companies track patient activity and ensure the clinical supply chain runs smoothly with international studies. We have added significant value by playing a critical role in the successful integration of eClinical solutions for this virtual Biopharma organization." said Shawn Blackburn, President and Co-founder of YPrime.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
